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REPLY
We agree with Dr. Davila that the pathogenesis and medical
treatment of chronic Chagas’ disease is complex and warrants
further research. In our study, which included only a small number
of patients with Chagas’ disease, there was no significant difference
in sympathetic activation between Chagas and non-Chagas etiol-
ogies of heart failure (Fig. 2A of reference 1). This finding is in
agreement with some (2,3), but not all (4) prior investigations. Of
note, uniquely in our study, efferent muscle sympathetic nerve
activity was measured directly utilizing microneurography, a sensi-
tive and reproducible technique, rather than indirectly with plasma
norepinephrine levels. Studies of the sympathetic activation in
Chagas’ disease, which include patients with and without overt
systolic dysfunction, may be able to distinguish between sympa-
thetic dysregulation attributable to T. cruzi infiltration of cardiac
nerves/autonomic ganglia and that attributable to the cardiac
dysfunction present late in Chagas’ disease.
Although many hypotheses have been advanced to explain the
sympathetic activation in heart failure, including baroreceptor
dysfunction, overactivity of the arterial and/or muscle chemore-
ceptors, or abnormalities in the “heart failure milicu,” the exact
mechanisms have not been established. It remains unknown
whether the same mechanisms underlie the sympathetic activation
in Chagas’ heart disease. Finally, the findings in our study lend
support to the concept that, regardless of the etiology of left
ventricular dysfunction and heart failure, a chronic exercise regi-
men is sympatholytic and beneficial. Studies enrolling larger
numbers of patients with Chagas’ heart disease are underway in our
laboratory in the hope of answering this question definitively.
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Assessment of Diastolic Function
Using Myocardial Velocity Gradient
I read with interest an editorial comment by Dr. Shah (1)
regarding a study on myocardial velocity gradient (MVG) and left
ventricular dysfunction (2). I agree with his comment that no
noninvasive measure of “pure” diastolic function has yet been
achieved.
In his comment, Dr. Shah stated that diastolic MVG measure-
ment was first reported by Fleming et al. (3) as being somewhat
insensitive to preload or atrial filling pressures. To my knowledge,
however, in 1994, MVG was introduced merely for the evaluation
of myocardial contractility. Fleming et al. compared the velocity
gradient with wall-thickness change to validate the new method-
ology (3). The application of MVG to assess diastolic dysfunction
had to wait until the report by Palka et al. (4) differentiating
hypertrophic cardiomyopathy from athletes’ hearts, in which,
however, they did not assess the effects of preload alterations.
Relative independence of MVG from preload alterations as com-
pared to transmitral flow patterns was first reported by Shimizu et
al. (5) in 1998. In addition, I would like to emphasize that a robust
aspect of the tissue Doppler technique is the potential to assess
regional, rather than global, diastolic function noninvasively,
which should be validated and clinically applied in the near future.
Although the editorial comment by Dr. Shah raises an impor-
tant issue in the assessment of diastolic function and thus is very
informative, I am afraid his statement on the application of MVG
measurements for the assessment of diastolic function seems to be
inaccurate.
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